The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction
18 March 2022 (07:45 - 19:55)
Organised by:
About the speaker
St Antonius Hospital, Nieuwegein (Netherlands (The))
4 More presentations in this session
Doctor P. Capranzano (Catania, IT)
Professor K. Huber (Vienna, AT)
Access the full session
The Event
ESC Acute CardioVascular Care 2022
18 March - 19 March 2022
